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NSCLC patients with known targetable molecular mutations is 
treatment of limited metastatic progression or 
oligoprogression.  This is due to the fact that most patients 
with treatable mutations in NSCLC progress in a limited 
number of metastases.  Ablation of these metastases has 
been shown to allow patients to remain on therapy longer 
thereby extending the time to the next line of therapy.  
Melanoma and Renal Cell Carcinoma, classically described 
“radioresistant” histologies, respond well to ablative 
radiation.  Ablation of all known metastases has resulted in 
high (80-90%) rates of treated tumor control.  Comparative 
analyses of metastastic melanoma patients treated with 
metastasectomy versus standard of care demonstrated 
improved survival for those treated with removal of 
metastases.  However this was prior to the advent of 
improved immunomodulatory and targeted agents for 
metastatic melanoma.  Furthermore, treatment of 
oligometastases with radiation has the potential to act as an 
immunosensitizer, stimulating the immune system and 
enhancing the response to immunomodulatory agents, 
perhaps inducing an abscopal effect.  
Evidence also shows that oligometastases are common in 
prostate cancer.  Ongoing studies are determining if ablative 
therapy to all known prostate oligometastases can delay the 
onset of androgen deprivation therapy, limiting the time, 
side effects and cost associated with treatment. 
 There are other roles for treatment of oligometastases 
beyond improvements in survival vs standard therapies.  Many 
patients are not candidates for standard therapies due to 
medical comorbidity.  Other patients, intolerant of the side 
effects of “targeted therapies”, are left with few treatment 
options.  Ablation of all metastases through surgery if 
feasible and possible or radiation can serve as another line of 
therapy to prolong disease free intervals.   
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Although the term 'oligometastasis' was coined in the 1990's, 
the first reports of treating limited metastatic disease with 
surgical resection originated six decades earlier. Several 
modalities are available to treat metastatic lesions, including 
surgical resection, stereotactic radiotherapy, conventional 
radiotherapy, and radiofrequency ablation. 
Numerous studies have reported 'better than expected' 
survival outcomes after ablation of limited metastatic 
disease, encompassing patients with varied histologic 
subtypes and metastatic locations. However, significant 
controversies remain, as it is unclear as to the extent of 
which the 'better than expected' survival is due to the 
treatments themselves, or merely due to selection of very fit 
patients with indolent-behaving tumors. The goal of this 
presentation is to review the uncertainties associated with 
the oligometastatic state, the natural history of untreated 
oligometastatic disease, current and past clinical trials, and 
future areas of research.  
 
 
 
 
 
 
 
 
 
 
Symposium with Proffered Papers: Immunotherapy and 
radiotherapy  
 
 
SP-0498   
Ablative radiation-mediated tumour control depends on 
DNA sensing and T cell responses 
Y. Fu1 
1University of Chicago, Deaprtment of Pathology, Chicago, 
USA  
 
It is thought that ablative radiotherapy (RT), used for rapid 
control tumor growth, induces genotoxic stress and mitosis 
crisis leading to prolonged dormancy of irradiated tumor at 
local and distal site in most patients. We have unexpectedly 
observed that initial reduction of tumor burden following 
ablative RT also depends largely on type I IFN for CTL.  
Targeting tumor with IFN can control tumor growth through 
initiating a coordinated innate and adaptive immune attack 
against tumor cells.  However, the mechanism for radiation-
mediated type I IFN induction remains unclear. Here, we 
demonstrated that STING, but not MYD88, was required for 
type I IFN-dependent antitumor effects of radiation. STING in 
dendritic cells (DCs) controlled radiation-mediated IFN-β 
induction and was activated by irradiated-tumor cells. The 
cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) 
mediated DCs sensing of irradiated-tumor cells. Moreover, 
STING was essential for radiation-induced adaptive immune 
responses, which relied on type I IFN signaling on DCs. 
Exogenous IFN-β treatment rescued cGAS/STING-deficient 
immune responses. Accordingly, enhancing STING signaling by 
cGAMP administration promoted antitumor efficacy of 
radiation. Our results reveal that the molecular mechanism 
of radiation-mediated antitumor immunity depends on a 
proper cytosolic DNA-sensing pathway, pointing towards a 
new understanding of radiation and host interactions. 
Furthermore, we uncover a new strategy to improve 
radiotherapy by cGAMP treatment.  RT induced IFN can also 
upregulate PD-L1 that suppress T cell-mediated damage and 
develop radiation resistance for relapse over time.  Anti-PDL-
1 antibody can greatly reduce radiation resistance leading to 
complete tumor regression.  Furthermore, our study 
challenges the rationale for current radio/chemotherapy 
strategies and highlights the importance of immune 
activation in preventing tumor relapse.   
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Cells respond to radiation. The best known pathways involve 
DNA repair and anti-apoptotic activities. These have different 
effects on the cell, its environment and the resulting immune 
response. We will discuss a new mechanism of DNA repair 
control that makes cells less responsive to radiation and DNA 
damaging chemotherapies. In addition, local radiotherapy 
can boost antibody-based triggering of immune responses to 
tumors but also makes the cells and environment more 
susceptible for CTL based therapies. This has allowed us to 
perform genome-wide screens to identify new and unknown 
factors controlling DNA repair and susceptibility to DNA 
damaging regimes in cancer therapy. We will discuss how 
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radiotherapy can manipulate these and speculate on the 
application of radio-immunotherapy in the control of cancer. 
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Purpose/Objective:Despite therapeutic advances in 
radiotherapy, the control of metastasis, is still a major 
challenge in cancer management. In order to develop more 
efficient therapies to counteract cancer cell invasion and 
metastasis, we need to understand the contribution of the 
tumour microenvironment. We are particularly interested on 
the effect of radiotherapy on macrophage behavior and how 
irradiated macrophages may modulate cancer cell activities 
and their response to radiotherapy. 
Materials and Methods: In order to address this question, we 
subjected primary human monocyte-derived macrophages to 
conventional doses of ionizing radiation, as used for cancer 
patient's treatment, and characterized macrophage 
functionality. The impact of irradiated macrophages on 
cancer cell activities, namely invasion and motility was also 
investigated, through Matrigel-invasion assay and time-lapse 
microscopy, respectively. 
Results: Our results evidence that radiation induces 
macrophage DNA damage, through H2AX-phosphorylation, 
without causing apoptosis. Instead, the increased expression 
of the anti-apoptotic protein Bcl-xL may contribute to 
irradiated macrophage pro-survival activity. Together, 
macrophage MMP-2 and 9 activities are not affected by 
ionizing radiation. Finally, we are also focused on the effect 
of ionizing radiation on macrophage proteome. Different 
proteomic approaches revealed that irradiated macrophages 
present altered expression levels of some metabolism-related 
proteins, which are currently under investigation. 
Nevertheless, irradiated macrophages are still able to 
promote cancer cell invasion and its conditioned medium 
increases motility of cancer cells.  
Conclusions: In summary, our results demonstrate that 
although the ionizing radiation doses used in the present 
work induce DNA damage, macrophages are still functional. 
In fact, irradiated macrophages are still able to promote 
cancer cell activities, namely invasion and motility. Current 
research on identification of cytokines and chemokines 
differentially expressed in macrophages upon ionizing 
radiation will complement these findings. Furthermore, this 
work will allow a better understanding on how ionizing 
radiation affects macrophage-cancer cell communication, 
opening perspectives for new therapeutic strategies that 
could be coupled with radiotherapy. 
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Purpose/Objective: The gastrin-releasing peptide 
receptors(GRPR) are up-regulated in many cancers, including 
prostate, colon, gastric, breast, pancreatic, and small cell 
lung cancers. Because bombesin binds to GRPR with high 
affinity, bombesin analogues have been labeled with various 
radionuclides for a targeted radiotherapy. The present study 
describes a new radiolabeled bombesin analogue for 
treatment of GRPR-overexpressing prostate tumors. 
Materials and Methods: A novel peptide was synthesized 
using a solid-phase synthetic method, and radiolabeled with 
177Lu, which was produced by the HANARO research reactor 
(thermal neutron flux of 1.8 × 1014 n·cm-2·s-1). The 
pharmacokinetic characteristics and therapeutic efficacy of 
the radiolabeled peptide were evaluated using PC-3 human 
prostate carcinoma cells-xenografted mice. 
Results: The purity of the synthesized peptide was exceeded 
98%, and it was radiolabeled with 177Lu at a high 
radiochemical purity (> 98%). The radiolabeled peptide 
showed in vitro nanomolar binding affinity on GRPR. It was 
highly accumulated in PC-3 tumors in vivo, and rapidly 
excreted from the blood pool. As a result, PC-3 tumor was 
specifically visualized by SPECT/CT imaging at 1 hr p.i. (Fig. 
1.). In addition, the radiolabeled peptide significantly 
inhibited the PC-3 tumor growth (P < 0.05) without 
treatment-related toxicities, except for slight 
glomerulopathy. 
 
 
Fig. 1. SPECT/CT images of PC-3-bearing mice using 177Lu-
labeled bombesin analogue. 
Conclusions: The pharmacokinetic, imaging, and therapy 
studies suggest that a novel 177Lu-labeled peptide has a 
promising characteristics for the targeted radiotherapy of 
GRPR-overexpressing prostate tumors.  
 
 
